SEMA7A and glioma: The research described that Semaphorin 7A (SEMA7A) was exposed to the surface of patient-derived glioma-associated stem cells (GASC) EVs and increased the activity of GSC through the interaction between integrin β1 and GSC in the microenvironment [84].